Navigation Links
Analysis Confirms Avandia May Harm the Heart

THURSDAY, March 17 (HealthDay News) -- A new analysis confirms that those who take the diabetes drug Avandia are more likely to develop heart problems and die than those who take a similar type of diabetes medication.

"The effect on public health may be considerable," the analysis authors wrote.

Avandia (rosiglitazone) helps control blood sugar levels in the body, and is prescribed for patients with type 2 diabetes. Studies in recent years have differed about whether it boosts the risk of heart disease and death.

In response to growing concerns over the drug's cardiovascular effects, U.S. health officials in September restricted the use of Avandia to patients with type 2 diabetes who cannot control their disease on other medications.

In the new analysis, researchers looked at the results of 16 studies that involved 810,000 users of Avandia or Actos (pioglitazone), a similar diabetes medication. The findings appear online March 17 in the BMJ.

The researchers found a "modest but statistically significant increase" in the odds of certain heart conditions in those who took Avandia. The risk of heart attack rose by 16 percent and increased 23 percent for congestive heart failure. Overall, mortality rates rose 14 percent.

Avandia is a common drug, with about 3.8 million prescriptions a year in the United States.

The analysis authors cautioned that Actos carries its own risks. Like Avandia, it's been linked to a doubling of risk of fracture in women. And researchers worry that it may slightly boost the risk of bladder cancer.

"Patients should review this study with their physician to gain a better understanding of how their personal circumstances may or may not be reflected in the study, and talk to their physicians about the risks versus the benefit of taking the drug," said Dr. Debra Wertz, outcomes research manager for HealthCore Inc., the research subsidiary of the insurance company WellPoint.

Wertz co-authored a 2010 study that found no significant differences in risk of heart attack, heart failure or death in patients who took the two drugs.

"One thing to consider is that the HealthCore study evaluated a population that is commercially insured and potentially younger [most were under 65] and healthier" than the studies analyzed in the meta-analysis, Wertz noted.

More information

For more about diabetes, try the U.S. National Library of Medicine.

-- Randy Dotinga

SOURCES: Debra Wertz, Pharm.D., outcomes research manager, HealthCore Inc., Wilmington, Del.; March 17, 2011, BMJ

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Kaiser Analysis Finds Record Medicaid Enrollment Growth in 2009
2. New approach to immune cell analysis seen as first step to better distinguish health and disease
3. National Center for Policy Analysis and Salem Radio Network Deliver One Million Emails to Congress to Stop ObamaCare
4. Pregnancy for breast cancer survivors: Meta-analysis reveals it is safe and could improve survival
5. Improved device provides more rapid, comprehensive analysis of circulating tumor cells
6. Know What Works with Semantic Design's Test Coverage Analysis Tool for C#/.Net
7. Social Media Network Analysis Workshop
8. University of Miami College of Engineering to develop new methods for data analysis
9. Biosensor chip enables high-sensitivity protein analysis for disease diagnosis
10. MetaGeek Announces Chanalyzer Pro Spectrum Analysis Software for Wi- Spy, Adds Device Classification, Device Finder and Automated Reports
11. Voice Analysis May Allow Early Detection of Parkinsons
Post Your Comments:
Related Image:
Analysis Confirms Avandia May Harm the Heart
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted by an ... IL, UV Angel is evaluating the efficacy of its product and its disinfection protocol. ... 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic medical ...
(Date:11/25/2015)... ... November 25, 2015 , ... "When I ... regular bras were incredibly uncomfortable," said an inventor from Bronx, N.Y. "In order ... developed the patent-pending RECOVERY BRA for added comfort and support. The bra is ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... on providing comprehensive solutions involving adult stem cell therapies to patients with chronic ... the “Regenestem” name as a Registered Trademark (RTM). , Organizations are required to ...
(Date:11/24/2015)... , ... November 24, 2015 , ... Dr. Todd S. ... offer laser services to many of his patients. Dr. Afferica now uses the BIOLASE ... reduce the amount of time the doctor uses other traditional cutting tools, such as ...
(Date:11/24/2015)... ... November 24, 2015 , ... In an article published ... that determine which patients are or are not eligible for bariatric surgery. The article ... over 40, are more than 100 pounds overweight, or have a BMI of 35 ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... , November 24, 2015 ... --> adds Latest Guidebook for ... of 217 pages published in November 2015 to ... online business intelligence library at . ... of the fastest growing global economies with a ...
(Date:11/24/2015)... 24, 2015  Ascendant Solutions, Inc. (Pink Sheets: ASDS ... of Directors has declared a special 1 percent stock dividend ... payable December 14, 2015, to shareholders of record December 7, ... additional shares of common stock. --> ... a strong endorsement of our confidence in Ascendant,s growth strategy ...
(Date:11/24/2015)... Nov. 24, 2015 Diplomat Pharmacy, Inc. (NYSE: DPLO) ... of Clinical Services, Education and Human Resources will be presenting ... Oncology Drugs: Health Plan Strategies for a Dynamic Market" on ... Fenrick , a consultant with the Cambridge Advisory Group, where ... The webinar will discuss the rapid growth ...
Breaking Medicine Technology: